Cutaneous T-cell lymphoma and emerging therapies

Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma (CTCL), characterized by a monoclonal proliferation of mature, skin-homing malignant T lymphocytes. Clinically in early stages MF presents with patches and plaques. Later stages are characterized by the onset of tumors and erythroderma eventually with blood, lymph node and/or systemic involvement. In recent years considerable progress has been made in understanding the pathogenetic aspects of MF, resulting in the development of new therapeutic options. Although to date there is no curative treatment for MF, new strategies allow us to achieve remissions even in heavily pretreated patients. This article provides an overview of recent research developments and therapeutic strategies for MF.

Section editor:Michael Roberts – School of Medicine, University of Queensland, Australia